期刊
出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.2016265118
关键词
EphB receptor; drug repurposing; neuropathic pain; crystallography
资金
- US Department of Energy, Office of Biological and Environmental Research [DE-AC02-06CH11357]
- Kent Waldrep Center for Basic Research on Nerve Growth and Regeneration
Previous studies showed that tetracycline antibiotics demeclocycline, chlortetracycline, and minocycline can inhibit EphB1 kinase activity, which was further confirmed in vivo by inhibiting phosphorylation of EphB1 in mice and effectively blocking neuropathic pain. This suggests that these drugs could be repurposed for treating neuropathic pain and potentially other conditions that benefit from inhibition of EphB1 receptor kinase activity.
Previous studies have demonstrated that the synaptic EphB1 receptor tyrosine kinase is a major mediator of neuropathic pain, suggesting that targeting the activity of this receptor might be a viable therapeutic option. Therefore, we set out to determine if any FDA-approved drugs can act as inhibitors of the EphB1 intracellular catalytic domain. An in silico screen was first used to identify a number of tetracycline antibiotics which demonstrated potential docking to the ATP-binding catalytic domain of EphB1. Kinase assays showed that demeclocycline, chlortetracycline, and minocycline inhibit EphB1 kinase activity at low micromolar concentrations. In addition, we cocrystallized chlortetracycline and EphB1 receptor, which confirmed its binding to the ATP-binding domain. Finally, in vivo administration of the three-tetracycline combination inhibited the phosphorylation of EphB1 in the brain, spinal cord, and dorsal root ganglion (DRG) and effectively blocked neuropathic pain in mice. These results indicate that demeclocycline, chlortetracycline, and minocycline can be repurposed for treatment of neuropathic pain and potentially for other indications that would benefit from inhibition of EphB1 receptor kinase activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据